EP Patent

EP0272891A2 — Immunoglobulin conjugates

Assigned to Eli Lilly and Co · Expires 1988-06-29 · 38y expired

What this patent protects

A process for preparing a conjugate which is an immunoglobulin or immunoglobulin fragment with an acylated difluoronucleoside linked to it, the acylated difluoro­nucleoside being of the formula R₁ is hydrogen, C₁-C₄ alkyl, -COR₃, or -COXCO-; R₂ is hydrogen or -COXCO-; R₄ is…

USPTO Abstract

A process for preparing a conjugate which is an immunoglobulin or immunoglobulin fragment with an acylated difluoronucleoside linked to it, the acylated difluoro­nucleoside being of the formula R₁ is hydrogen, C₁-C₄ alkyl, -COR₃, or -COXCO-; R₂ is hydrogen or -COXCO-; R₄ is hydrogen, C₁-C₄ alkyl, amino, bromo, fluoro, chloro, or iodo; R₃ is hydrogen or C₁-C₄ alkyl; X is a bond, C₁-C₁₀ straight chain alkylene, C₂-C₁₀ branched alkylene, C₂-C₁₀ alkenylene, C₃-C₁₀ alkynylene, C₃-C₆ cycloalkylene, phenylene, or hydroxy-­substituted C₁-C₁₀ alkylene, and A is N or C-R₄; provided that one and only one of R₁ and R₂ is -COXCO-.

Drugs covered by this patent

Patent Metadata

Patent number
EP0272891A2
Jurisdiction
EP
Classification
—
Expires
1988-06-29
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.